GTCM
INKT icon

Gyon Technologies Capital Management’s MiNK Therapeutics INKT Stock Holding History

Gyon Technologies Capital Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,245
Closed -$189K – 420
2021
Q4 		$189K Buy
+4,245
New +$505K 0.03% 530

Other funds holding INKT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Gyon Technologies Capital Management's INKT Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of MiNK Therapeutics (INKT) in Q1 2022, closing a stake of 4,245 shares — an estimated $189K sold.

Gyon Technologies Capital Management first reported a position in INKT in Q4 2021 and held it in 1 quarter. The position peaked at $189K in Q4 2021. 25 funds tracked by Wall St. Rank hold INKT as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining MiNK Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 4,245 MiNK Therapeutics shares in Q1 2022, an estimated $189K.
  • Gyon Technologies Capital Management first reported a position in MiNK Therapeutics in Q4 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's MiNK Therapeutics position peaked at $189K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.